Skip to main content

Advertisement

SpringerLink
Log in

Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

We performed distal gastrectomy with D2 lymph node dissection, pathological stage was Stage IB (T2N0M0), in a 68-year-old male with gastric adenocarcinoma. We then monitored serum p53 antibody titers for 5 years and found it consistently decreased, without disease recurrence. Although the s-p53-Ab titer remained positive even after 2 years, it decreased to 16.5, 4.45, 2.66, 1.55, and 1.18 U/ml at 3 months, 7 months, 1 year, 2 years and 3 years after surgery, respectively. The s-p53-Ab titer finally converted from positive to negative at 31 months postoperatively without any sign of recurrence by computed tomography examination at 5 years after surgery. This case report shows that the changing pattern of s-p53-Ab titer after surgery may be useful to identify patients without recurrence. Further studies are required to gain a more precise understanding of the clinical impact of s-p53-Ab titer monitoring in gastric adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Shiota G, Ishida M, Noguchi N, et al. Clinical significance of serum p53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol. 1998;99:41–51.

    CAS  PubMed  Google Scholar 

  2. Shimizu K, Ueda Y, Yamagishi H. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer. 2005;8:214–9.

    Article  CAS  PubMed  Google Scholar 

  3. Nakajima K, Suzuki T, Shimada H, et al. Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumour Biol. 1999;20:147–52.

    Article  CAS  PubMed  Google Scholar 

  4. Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.

    Article  PubMed  Google Scholar 

  5. Shimada H, Nagata M, Cho A, et al. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957–61.

    Article  CAS  PubMed  Google Scholar 

  6. Maehara Y, Kakeji Y, Watanabe A, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer. 1999;85:302–8.

    Article  CAS  PubMed  Google Scholar 

  7. Werner S, Chen H, Tao S, et al. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2015;136:2243–52.

    Article  CAS  PubMed  Google Scholar 

  8. Tokunaga R, Sakamoto Y, Nakagawa S, et al. The utility of tumor marker combination, including serum p53 antibody, in colorectal cancer treatment. Surg Today. 2017;47:636–42.

    Article  CAS  PubMed  Google Scholar 

  9. Suzuki T, Shimada H, Ushigome M, et al. Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol. 2016;9:55–8.

    Article  PubMed  Google Scholar 

  10. Shimada H, Ochiai T, Nomura F. Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.

    Article  PubMed  Google Scholar 

  11. Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.

    Article  Google Scholar 

  12. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.

    Article  CAS  PubMed  Google Scholar 

  13. Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.

    Article  PubMed  Google Scholar 

  14. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49:673–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan

    Kenji Murayama, Tatsuki Nanami, Takashi Suzuki, Yoko Oshima, Satoshi Yajima & Hideaki Shimada

  2. Department of Clinical Oncology, Toho University Graduate School of Medicine, 6-11-1 Omori-nishi, Ota-ku, Tokyo, Japan

    Kenji Murayama & Hideaki Shimada

  3. Department of Surgical Pathology, Toho University School of Medicine, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan

    Tetsuo Nemoto

Authors
  1. Kenji Murayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsuki Nanami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoko Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Yajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsuo Nemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideaki Shimada.

Ethics declarations

Conflict of interest

Hideaki Shimada received a research grant from Medical and Biological Laboratories, Co., Ltd. The other co-authors declare no conflict of interest.

Human/animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments.

Informed consent

Informed consent was obtained from the patient for inclusion in the study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

12328_2017_749_MOESM1_ESM.jpg

Supplementary material 1 The relationship between each assumptive half-life image and the changing pattern of s-p53-Abs after surgery. The s-p53-Ab changing line is located more to the right side than the 50-day half-life line (JPG 55 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murayama, K., Nanami, T., Suzuki, T. et al. Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery . Clin J Gastroenterol 10, 357–360 (2017). https://doi.org/10.1007/s12328-017-0749-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-017-0749-9

Keywords

Search

Navigation